Plasma Neurofilament Light : A Marker of Neurodegeneration in Mild Behavioral Impairment
BACKGROUND: Assessing neuropsychiatric symptoms (NPS) in older adults is important for determining dementia risk. Mild behavioral impairment (MBI) is an at-risk state for cognitive decline and dementia, characterized by emergent NPS in later life. MBI has significantly higher dementia incidence than late life psychiatric conditions. However, its utility as a proxy for neurodegeneration has not been demonstrated. Plasma neurofilament light (NfL) is a validated biomarker of axonal damage, and has been shown to associate with hallmarks of neurodegeneration.
OBJECTIVE: The purpose of this investigation was to identify associations between NfL rate of change and the presence of MBI symptomatology.
METHODS: We evaluated the association of MBI with changes in NfL in a cohort (n = 584; MBI + n = 190, MBI- n = 394) of non-demented participants from the Alzheimer's Disease Neuroimaging Initiative. MBI was determined by transforming Neuropsychiatric Inventory Questionnaire items using a published algorithm. Change in NfL was calculated over 2 years.
RESULTS: Time*MBI status was the only significant interaction to predict change in NfL concentrations (F(1,574) = 4.59, p = 0.032), even after controlling for age, mild cognitive impairment, and demographics. Analyses reclassifying 64 participants with new onset MBI over 2 years similarly demonstrated greater increases in NfL (F(1,574) = 5.82, p = 0.016).
CONCLUSION: These findings suggest MBI is a clinical proxy of early phase neurodegeneration with putative utility in identifying those at dementia risk. MBI can be used as a case ascertainment approach to capture those at high risk for cognitive decline and dementia, and is an important construct for clinicians dealing with cognitive and neuropsychiatric symptomatology in older adults.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Journal of Alzheimer's disease : JAD - 76(2020), 3 vom: 21., Seite 1017-1027 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Naude, James P [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.06.2021 Date Revised 29.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3233/JAD-200011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311759084 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311759084 | ||
| 003 | DE-627 | ||
| 005 | 20240329233128.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3233/JAD-200011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1354.xml |
| 035 | |a (DE-627)NLM311759084 | ||
| 035 | |a (NLM)32597801 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Naude, James P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plasma Neurofilament Light |b A Marker of Neurodegeneration in Mild Behavioral Impairment |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.06.2021 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Assessing neuropsychiatric symptoms (NPS) in older adults is important for determining dementia risk. Mild behavioral impairment (MBI) is an at-risk state for cognitive decline and dementia, characterized by emergent NPS in later life. MBI has significantly higher dementia incidence than late life psychiatric conditions. However, its utility as a proxy for neurodegeneration has not been demonstrated. Plasma neurofilament light (NfL) is a validated biomarker of axonal damage, and has been shown to associate with hallmarks of neurodegeneration | ||
| 520 | |a OBJECTIVE: The purpose of this investigation was to identify associations between NfL rate of change and the presence of MBI symptomatology | ||
| 520 | |a METHODS: We evaluated the association of MBI with changes in NfL in a cohort (n = 584; MBI + n = 190, MBI- n = 394) of non-demented participants from the Alzheimer's Disease Neuroimaging Initiative. MBI was determined by transforming Neuropsychiatric Inventory Questionnaire items using a published algorithm. Change in NfL was calculated over 2 years | ||
| 520 | |a RESULTS: Time*MBI status was the only significant interaction to predict change in NfL concentrations (F(1,574) = 4.59, p = 0.032), even after controlling for age, mild cognitive impairment, and demographics. Analyses reclassifying 64 participants with new onset MBI over 2 years similarly demonstrated greater increases in NfL (F(1,574) = 5.82, p = 0.016) | ||
| 520 | |a CONCLUSION: These findings suggest MBI is a clinical proxy of early phase neurodegeneration with putative utility in identifying those at dementia risk. MBI can be used as a case ascertainment approach to capture those at high risk for cognitive decline and dementia, and is an important construct for clinicians dealing with cognitive and neuropsychiatric symptomatology in older adults | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Alzheimer’s disease | |
| 650 | 4 | |a mild behavioral impairment | |
| 650 | 4 | |a mild cognitive impairment | |
| 650 | 4 | |a neurodegeneration | |
| 650 | 4 | |a neurofilament light | |
| 650 | 4 | |a neuropsychiatric symptoms | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Neurofilament Proteins |2 NLM | |
| 700 | 1 | |a Gill, Sascha |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a McGirr, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Forkert, Nils D |e verfasserin |4 aut | |
| 700 | 1 | |a Monchi, Oury |e verfasserin |4 aut | |
| 700 | 1 | |a Stys, Peter K |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Eric E |e verfasserin |4 aut | |
| 700 | 1 | |a Ismail, Zahinoor |e verfasserin |4 aut | |
| 700 | 0 | |a Alzheimer’s Disease Neuroimaging Initiative |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Alzheimer's disease : JAD |d 1998 |g 76(2020), 3 vom: 21., Seite 1017-1027 |w (DE-627)NLM097527327 |x 1875-8908 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2020 |g number:3 |g day:21 |g pages:1017-1027 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3233/JAD-200011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2020 |e 3 |b 21 |h 1017-1027 | ||